Nick Eliovits, DermBiont co-founder and CBO
October 18, 2022 04:48 AM EDT
Financing
Startups
R&D

Scoop: With in­vestor in­ter­est dried up in mi­cro­bio­me ther­a­pies, DermBiont piv­ots to oth­er top­i­cals and nears close of Se­ries B

Kyle LaHucik

Senior Reporter

DermBiont axed tri­als of its orig­i­nal lead der­ma­tol­ogy gel, the biotech con­firmed to End­points News, and with lit­tle in­vestor ap­petite for mi­cro­bio­me-based ther­a­pies, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times